Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.

Direct-acting antiviral therapy prolongs survival in HCV-infected HCC patients

21 Oct 2019

Use of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.

The retrospective study included 797 patients with HCV-related HCC, among whom 383 (48.1 percent) received DAA therapy. All patients achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy.

There were 43 deaths that occurred during 941 person-years of follow-up in the DAA group in comparison with 103 deaths during 526.6 person-years of follow-up in the nontreated group (crude rate ratio, 0.23, 95 percent CI, 0.16–0.33).

Inverse probability-weighted analyses revealed DAA therapy to be associated with a significant decrease in the risk of death (hazard ratio [HR], 0.54, 95 percent CI, 0.33–0.90). This protective association differed by sustained virologic response (SVR) to DAA therapy, such that mortality risk was reduced in patients who achieved SVR (HR, 0.29, 0.18–0.47) but not in those without SVR (HR, 1.13, 0.55–2.33).

Median time from HCC complete response to DAA initiation was 7.7 months, with 20.2 percent of participants treated within 3 months, 21.5 percent between 3 and 6 months, 25.5 percent between 6 and 12 months, and 32.9 percent >12 months after HCC complete response. A total of 79.4 percent of DAA-treated patients achieved SVR, while 11.5 percent had treatment-failure and 9.1 percent had no documented assessment of SVR.

The present data suggest that HCV-infected patients with a history of HCC may benefit from DAA therapies, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.